Harashima SI, et al. - In this phase IV study, the researchers intended to assess the efficacy and safety of the sodium-glucose co-transporter-2 (SGLT2) inhibitor canagliflozin as add-on therapy in Japanese patients with type 2 diabetes mellitus (T2DM) and inadequate glycaemic control with a glucagon-like peptide-1 receptor agonist {GLP-1RA} (≥12 weeks). For this investigation, patients received canagliflozin 100 mg once daily for 52 weeks. Change in glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), body weight, systolic blood pressure (SBP) and HDL cholesterol from baseline to week 52 were the included efficacy endpoints. In Japanese patients with T2DM, the long-term combination of canagliflozin with a GLP-1RA was effective and well tolerated.